Several studies have shown that pharmacological inhibition or gene deletion of PARP-1 could prevent tissue damage induced by oxidative stress associated with several diseases like stroke, diabetes, myocardial ischemia-reperfusion and Parkinson's disease [35]–[37]. This evidence concerns the gene PARP1 and Parkinson disease.